Compass Therapeutics Stock Skyrockets 108% in a Month: Here's Why

Core Viewpoint - Shares of Compass Therapeutics (CMPX) have increased by 108.3% in one month due to positive updates on pipeline development and cash position, reflecting strong investor expectations for the company's potential in oncology-focused therapeutics [1] Group 1: Lead Pipeline Program - CMPX's lead candidate, tovecimig (CTX-009), is in a phase II/III study with paclitaxel for advanced biliary tract cancer (BTC) patients who have had one prior chemotherapy [2] - The study aims to evaluate the safety and efficacy of the tovecimig/paclitaxel combination compared to paclitaxel alone in second-line treatment settings [2] - Top-line data is expected to be reported in the U.S. by the end of Q1 2025, with the combination having received FDA's Fast Track designation for BTC treatment [4] Group 2: Other Pipeline Programs - Compass Therapeutics is planning a phase II study of CTX-471 (CD137 agonist) for tumors expressing NCAM in mid-2025 [8] - An early-stage dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody) has completed patient enrollment in its third dosing cohort [8] - The novel PD-1 x VEGF-A bispecific antibody, CTX-10726, is set for investigational new drug application submission by the end of the year, with initial clinical data expected in 2026 [9] Group 3: Financial Position - As of December 31, 2024, Compass Therapeutics estimates a cash balance of $127 million, which is projected to support operations into Q1 2027 [9] Group 4: Stock Performance - CMPX shares have surged 77.6% over the past three months, contrasting with a 7.1% decline in the industry [3]